At 30 minutes before the close of the market on Monday, EPIX will announce Phase III results in a presentation before the American College of Cardiology. After the market close, they'll host a conference call for investors.
<<CAMBRIDGE, Mass.--(BW HealthWire)--March 13, 2002--Phase III clinical trial results of magnetic resonance angiography (MRA) enhanced by EPIX Medical's lead-product in development, MS-325 will be presented at the 2002 American College of Cardiology Annual Scientific Session.
``Results of a Dose-Ranging Diagnostic Trial of Magnetic Resonance Angiography With MS-325, a Blood Pool Contrast Agent, for the Detection of Vascular Occlusive Disease in the Aortoiliac Region'' will be presented by Emile R. Mohler, III, MD on Monday, March 18, 2002 at 3:30 pm EST (Georgia World Congress Center, Hall G).
EPIX Medical will host a live webcast of its conference call discussing the Phase III clinical trial results, and providing an update on the MS-325 clinical trial program, at 5:30 pm EST on March 18, 2002. The press release and webcast can be accessed by visiting the EPIX website at www.epixmed.com.>>
Looking at the stock chart, you'll see that the stock rebounded sharply starting in November, but has been in a holding pattern (near 52-week high) for the past couple months:
quote.yahoo.com
Here's what I'd like to believe:
1) The heavy buying in November may have been due in part to leaks from the scientific community about the Phase III trial results.
2) The news on Monday is therefore likely to be good.
3) The stock will rally on the news this Monday and will shoot through the 52-week high.
4) Because there is no resistance above the 52-week high, and because there is a healthy base at the current trading range, the stock will rise into a sustained rally.
I hope I'm right. I've been long the stock for a good while.
Marc |
